Latham & Watkins represented Merus N.V. in the transaction. Merus N.V. (Merus), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), has announced…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
